drugset / Trial / NCT01181505
STUDY The Effect of HNF-4A G60D Variant on the In VIVO CYP2D6 Activity By Tolterodine Pharmacokinetic Study
Non-randomizedParallel-groupOpen-labelBasic science
Summary
This study was to investigate the pharmacokinetics of tolterodine, substrate of CYP2D6 in healthy subject in relation to the presence of HNF-4A G60D variant.
Timeline
- Start
- 2007-01
- Primary completion
- 2008-06
- Completion
- 2008-06
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | Tolterodine | Small molecule | 2 mg | Oral |
Indications
No indication recorded.